ReviewCell2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Open access · hybridAbstract readReview
In one paragraph
Review in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 792 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
792citing papers in PubMed, 2 pooled it
45.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
792 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,152 citations in OpenAlex.
- Efficacy and safety of immunotherapy monotherapy versus combination regimens in recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.Nature medicine · 2025Trial
- INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- TNF-α deficiency underlies NK cell dysfunction in colorectal cancer.Oncoimmunology · 2026Article
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Immune cells in keloids: mechanisms and potential treatments.Annals of medicine · 2026Review
- Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions.Annals of medicine · 2026Review
- Application of artificial intelligence in head and neck squamous cell carcinoma.Annals of medicine · 2026Review
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation.Biomarker research · 2026Review
- Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell reports. Medicine · 2026Article
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells.Molecular pharmaceutics · 2026Article
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
732 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
30 authors at 7 institutions in 1 country.
Pascale AndréInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France. Electronic address: pascale.andre@innate-pharma.fr.
Caroline DenisInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Caroline SoulasInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Clarisse Bourbon-CailletInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Julie LopezInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Thomas ArnouxInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Mathieu BléryInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Cécile BonnafousInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Laurent GauthierInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Ariane MorelInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Benjamin RossiInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Romain RemarkInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Violette BresoInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Elodie BonnetInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Guillaume HabifInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Sophie GuiaAix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France.
Ana Ines LalanneUnité INSERM U932, Immunité et Cancer, Institut Curie, 75248 Paris Cedex 5, France.
Caroline HoffmannUnité INSERM U932, Immunité et Cancer, Institut Curie, 75248 Paris Cedex 5, France; Service ORL et Chirurgie cervico-faciale, Institut Curie, 75248 Paris Cedex 5, France.
Olivier LantzUnité INSERM U932, Immunité et Cancer, Institut Curie, 75248 Paris Cedex 5, France.
Jérôme FayetteCentre Léon Bérard, 69008 Lyon, France.
Agnès Boyer-ChammardInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Robert ZerbibInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Pierre DodionInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Hormas GhadiallyMedImmune, Ltd., Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK.
Maria Jure-KunkelMedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.
Yannis MorelInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France.
Ronald HerbstMedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.
Emilie Narni-MancinelliAix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France.
Roger B CohenAbramson Cancer Center, 3400 Civic Center Boulevard West Pavilion, Philadelphia, PA, USA.
Eric VivierInnate Pharma, 117 Avenue de Luminy, 13009 Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France; Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.
Innate Pharma (France) · FRCentre d’Immunologie de Marseille-Luminy · FRInstitut Curie · FRAbramson Cancer CenterAix-Marseille Université · FRCentre Léon Bérard · FRInserm · FR
Funding
European Research Council 694502
Abstract
Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8
Indexed as
Carcinoma, Squamous CellImmunotherapyNK Cell Lectin-Like Receptor Subfamily CAnimalsAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesCetuximabClinical Trials, Phase II as TopicHumansImmunity, CellularKiller Cells, NaturalMiceAntineoplastic Agents, ImmunologicalCetuximabNK Cell Lectin-Like Receptor Subfamily Ccancer immunotherapyCD8(+) T cellsimmunce checkpoint inhibitorinhibitory receptorslymphocytesnatural killer cellstherapeutic monoclonal antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.